Tricuspid valve disorders (TVDs) have historically been underrecognized by clinicians. However, recent years have seen increasing awareness of their clinical impact. This mini-review aims to briefly highlight some questions regarding TVDs, such as Review of tricuspid valve disorders, Decoding its trends, The gender and racial divide, Breaking barriers, Where you live matters, Surgery vs. minimally invasive options, Bridging the gap, and the underappreciated significance of TVDs and why they’re becoming a growing concern in the U.S. There is a significant change in perception of the tricuspid valve—from being the “forgotten valve” to being an important area of focus in cardiology as well as clinical medicine in general. With the aid of advanced imaging methods like echocardiography, CT, and MRI that show a clear and three-dimensional view of the tricuspid valve, there is a better understanding of both the prevalence and diagnostic precision of TVDs. Advancements involving more efficient and optimally timed treatment strategies are also occurring. Although medical and surgical approaches are still in use, developments such as transcatheter tricuspid valve interventions (TTVIs) are promising, particularly for high-risk patients with minimal improvement with surgical treatment. TVDs, especially tricuspid regurgitation, have gained widespread attention in the medical and research community, resulting in improved and evolving diagnostic and therapeutic progress to improve patient outcomes.

Resistant Kawasaki has been associated with the aggressive development of large coronary aneurysms, despite prompt treatment. In this paper, we present an infant who presented with resistant Kawasaki. Although initially he seemed to defervesce after the initial administration of intravenous immunoglobulin, he developed a new onset of fever, requiring a repeat dose of immunoglobulin. Coronary aneurysms developed rapidly, necessitating a second dose of immunoglobulins and second-line treatments such as anakinra and infliximab. High titers of COVID-19 antibodies have been a confounding factor in the management of that child, as the alternative diagnosis of multisystem inflammatory syndrome in children (MIS-C) was considered. Finally, the clinical and laboratory values were more in keeping with MIS-C.

L-Carnitine (LC) is integral to energy production and fatty acid metabolism, facilitating the transport of long-chain fatty acids into mitochondria for β-oxidation. It modulates metabolic pathways, including pyruvate dehydrogenase activity, proteolysis, and protein synthesis, while also having anti-inflammatory and antioxidant characteristics. LC can be commonly applied to win the battle against HIV and cancer cachexia. Also, it can be recruited with the aim of improving physical and cognitive functions in athletes and the elderly. Despite these benefits, long-term LC administration has been associated to cardiovascular risks due its conversion to trimethylamine-N-oxide (TMAO) by the gut microbiota. Elevated TMAO levels are linked to atherosclerosis, oxidative stress, and an increased risk of cardiovascular disease, diabetes, and chronic kidney disease. Managing TMAO levels using dietary treatments and gut microbiota-targeting techniques, such as probiotics, may reduce these risks. This comprehensive review presents the state-of-the-art information on LC’s dual role, emphasizing the balance between its therapeutic potential and the risks of prolonged supplementation. It aims to guide clinicians and researchers in optimizing LC’s benefits while addressing its long term cardiovascular safety concerns.